CITIC SEC maintains a "buy" rating on YUM CHINA (09987) with a target price of HK$432.
CITIC Securities believes that Yum China (09987) still has good long-term growth potential.
CITIC Securities has released a research report stating that it maintains a "buy" rating on YUM CHINA(09987), and continues to be optimistic about the company's long-term stable growth potential. With reference to the historical average valuation level (20-30xPE), the company is given a corresponding 2024 P/E ratio of 25 times, with a target price of HK$432. The bank believes that the KFC brand remains outstanding, and the company is expected to achieve high single to double digit CAGR in system sales and operating profits from 2024 to 2026 as indicated in investor meetings. EPS is also expected to achieve double digit CAGR, with further expansion of shareholder returns. The bank predicts an adjusted net profit of $1.06 billion USD in 2026, and the current price corresponds to P/E ratios of 18/17/16 times for 2024-26 respectively.
Related Articles

ZCZL Industrial Technology Group (00564) released annual performance, with net profit attributable to shareholders of approximately 4.306 billion yuan, a year-on-year increase of 9.2%.

CCT FORTIS-OLD(00138) announced annual performance, with a net loss attributable to shareholders of approximately 327 million Hong Kong dollars, a decrease of 17.4% compared to the previous year.

AIM VACCINE (06660) plans to apply for an A-share listing on the Shenzhen Stock Exchange, aiming to become the first stock of "H+ North".
ZCZL Industrial Technology Group (00564) released annual performance, with net profit attributable to shareholders of approximately 4.306 billion yuan, a year-on-year increase of 9.2%.

CCT FORTIS-OLD(00138) announced annual performance, with a net loss attributable to shareholders of approximately 327 million Hong Kong dollars, a decrease of 17.4% compared to the previous year.

AIM VACCINE (06660) plans to apply for an A-share listing on the Shenzhen Stock Exchange, aiming to become the first stock of "H+ North".

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


